RESUMEN
Diagnosis of lymph node metastases in pelvic lymph node dissection (PLND) is important for staging and treatment. Standard practice is to submit visible or palpable lymph nodes for histology. We assessed the added value of embedding all residual fatty tissue.Patients (n = 85) who underwent PLND for cervical (n = 50) or bladder cancer (n = 35) between 2017 and 2019 were included. Study approval was obtained (MEC-2022-0156, 18.03.2022, retrospectively registered).The median lymph node yield with conventional pathological dissection was 21 nodes (Interquartile range (IQR) 18-28). This led to discovery of positive lymph nodes in 17 (20%) patients. Extended pathological assessment found 7 (IQR 3-12) additional nodes, but did not result in identification of more node metastases.Histopathological analysis of residual fatty tissue harvested at PLND resulted in an increased lymph node yield, but not in the detection of additional lymph node metastases.
Asunto(s)
Pelvis , Neoplasias de la Vejiga Urinaria , Humanos , Metástasis Linfática/patología , Pelvis/patología , Escisión del Ganglio Linfático/métodos , Neoplasias de la Vejiga Urinaria/cirugía , Neoplasias de la Vejiga Urinaria/patología , Ganglios Linfáticos/patologíaRESUMEN
OBJECTIVE: To compare the effect of tibolone to conjugated estrogens with medroxyprogesterone-acetate (CEEâ+âMPA) on breast density, as a predictor for breast cancer risk, in women with a high risk of breast and ovarian cancer. METHODS: Women aged 30-50 (Nâ=â114) who had undergone risk-reducing salpingo-oophorectomy (RRSO) were randomized to tibolone or CEEâ+âMPA. RESULTS: Breast density decreased 46% after RRSO in untreated women, 39% after treatment with tibolone, and 17% after treatment with CEEâ+âMPA; the decrease in breast density after CEEâ+âMPA was significantly different compared with that of untreated women (Pâ=â0.017). CONCLUSIONS: A decline in breast density is seen after premenopausal RRSO despite the use of both CEEâ+âMPA or tibolone, although lower breast density is seen after tibolone use.